Curcuminoid supplementation on type 2 diabetes

Effects of curcuminoids on blood glucose, lipids, serum adipocyte fatty acid-binding protein and lipoprotein lipase in patients with type 2 diabetes: a double-blind, placebo-controlled trial

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN85826075

Enrollment

100

Registered

2010-10-25

Start date

2009-10-10

Completion date

Unknown

Last updated

2022-05-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 diabetes Nutritional, Metabolic, Endocrine Diabetes

Interventions

Eligible subjects were first sorted by blood glucose concentration and then randomised into two groups with a block size of 2, with random numbers generated by SPSS. The subjects in t

demethoxycurcumin, 18.85%

bisdemethoxycurcumin, 42.58%). The subjects in placebo group took capsules with placebo (starch) instead of curcuminoids at the same frequency and amount. The interve

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Aged 18 - 65 years, both male and female 2. Type 2 diabetes with fasting blood glucose greater than or equal to 7.0 mmol/L or postprandial blood glucose greater than or equal to 11.1 mmol/L 3. Current optimal therapeutic regimens lasting for at least 6 months

Exclusion criteria

Exclusion criteria: 1. A history of type 1 diabetes, malignancies, thyroid or any other endocrine diseases likely to interfere with the study 2. Diabetic ketosis acidosis and infection in recent 3 months 3. Pregnancy or breastfeeding 4. Information incompleted or unwillingness to attempt to comply with the intervention

Design outcomes

Primary

Measure	Time frame
1. The effects of curcuminoids on glucose metabolism: fasting glucose and insulin, 2-hour post prandial glucose , HOMA-IR and HbA1c(%) 2. The effects of curcuminoids on lipis metabolism: 2.1. Serum cholesterol, triacylglycerol, HDL-C, LDL-C, Apo A-I and Apo B 2.2. Serum LPL and AFABP 2.3. Serum FFA profile 2.4. Severity of fatty liver	—

Secondary

Measure	Time frame
1. Baseline characteristics: age, gender, BMI, waist circumference, waist-to-hip ratio, diabetes duration, blood pressure, drug treatment, cigarette use and physical activity level 2. Daily intake of nutrients by the subjects at baseline and after 3-month intervention 3. Blood biochemistry characteristics of the subjects at baseline and after 3-month intervention: red blood cell, white blood cell, hemoglobin, total protein, albumin, urea nitrogen, creatinine, alanine transaminase and aspartate transminase	—

Measure

Time frame

1. Baseline characteristics: age, gender, BMI, waist circumference, waist-to-hip ratio, diabetes duration, blood pressure, drug treatment, cigarette use and physical activity level 2. Daily intake of nutrients by the subjects at baseline and after 3-month intervention 3. Blood biochemistry characteristics of the subjects at baseline and after 3-month intervention: red blood cell, white blood cell, hemoglobin, total protein, albumin, urea nitrogen, creatinine, alanine transaminase and aspartate transminase

—

Countries

China

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026